Medifocus Inc. (MDFZF) 0.0840 $MDFZF
Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board
Marketwire Canada - Tue Jun 16, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB).
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board
Marketwired - Thu Jun 04, 8:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has established a Strategic Advisory Board (SAB) and has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, as one of the Company's Strategic Business Advisors.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Announces Option Agreement With Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy
Marketwired - Wed May 27, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has entered into an option agreement with Duke University regarding heat-activated and tumor targeted Immunotherapy. The two parties are actively negotiating an exclusive license to the Patent Rights of a Duke invention for the development of heat-activated and tumor targeted Immunotherapy for treatment of cancer and other diseases. This option to license and develop Duke's technology runs through December 30, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Closes Equity Offering
Marketwire Canada - Tue May 12, 10:48AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) today announced that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 13, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus Announces Retraction of Prior Press Release
Marketwire Canada - Mon May 11, 3:26PM CDT
Medifocus, Inc. (Medifocus) (OTCQX: MDFZF) (TSX VENTURE: MFS) issued a press release earlier today regarding an equity offering that inadvertently announced the completion of the offering. Medifocus hereby retracts this press release.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Announces Equity Offering
Marketwire Canada - Mon May 11, 2:08PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 11, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:41PM CDT
Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014
Marketwired - Tue Mar 24, 7:00AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the third fiscal quarter ending December 31, 2014.
MFS.VN: 0.100 (-0.020)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 8.31 (+0.23), ILMN: 219.45 (+2.28), HBIO: 5.34 (+0.16), PODD: 31.26 (+0.76), IART: 63.06 (+0.98), IVC: 20.62 (+0.25), IMRS: 0.02 (-0.01), INGN: 43.74 (+0.89), IDXX: 64.09 (+1.22), HRC: 54.12 (+0.74), HOLX: 38.71 (+0.75)
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Appoints Christopher Kaplan to Its Strategic Advisory Board
Marketwire Canada - Tue Jun 16, 7:30AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has appointed Christopher Kaplan as a member of the its recently formed Strategic Advisory Board (SAB).
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Appoints Joseph M. Chalil to Its Strategic Advisory Board
Marketwired - Thu Jun 04, 8:01AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical system and device company which announced recently that the Company is making a strategic transformation to become a biotechnology company by entering into the business of development and commercialization of heat activated and tumor targeted molecular/genetic therapeutics, announced today that the Company has established a Strategic Advisory Board (SAB) and has appointed Dr. Joseph M. Chalil, MD, MBA, FACHE, as one of the Company's Strategic Business Advisors.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Announces Option Agreement With Major Academic Medical Center to License Technology to Develop Heat Activated and Tumor Targeted Immunotherapy
Marketwired - Wed May 27, 7:00AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS), a medical systems and devices company that develops and commercializes focused heat thermotherapy systems for treatment of Benign Prostatic Hyperplasia (BPH) and breast cancer, today announced that the Company has entered into an option agreement with Duke University regarding heat-activated and tumor targeted Immunotherapy. The two parties are actively negotiating an exclusive license to the Patent Rights of a Duke invention for the development of heat-activated and tumor targeted Immunotherapy for treatment of cancer and other diseases. This option to license and develop Duke's technology runs through December 30, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Closes Equity Offering
Marketwire Canada - Tue May 12, 10:48AM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) today announced that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 13, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus Announces Retraction of Prior Press Release
Marketwire Canada - Mon May 11, 3:26PM CDT
Medifocus, Inc. (Medifocus) (OTCQX: MDFZF) (TSX VENTURE: MFS) issued a press release earlier today regarding an equity offering that inadvertently announced the completion of the offering. Medifocus hereby retracts this press release.
MFS.VN: 0.100 (-0.020)
Medifocus, Inc. Announces Equity Offering
Marketwire Canada - Mon May 11, 2:08PM CDT
Medifocus, Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) announces that it has closed a non-brokered private placement of 38,750,000 common shares (the Common Shares) at a price of $0.055 per Common Share for gross proceeds of up to $2,131,250. Commissions of $180,000 were paid to Asset Profits Limited and Bess Wide Holdings Limited for subscription originated by them. The net proceeds of $1,987,250 will be used for general working capital. The Private Placement was previously announced on March 27, 2015. Shares issued under the offering are subject to resale restrictions until September 11, 2015.
MFS.VN: 0.100 (-0.020)
Medifocus initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Mar 27, 8:41PM CDT
Medifocus, Inc. Announces Financial Results for the Nine Months Ending December 31, 2014
Marketwired - Tue Mar 24, 7:00AM CDT
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) (Medifocus or the Company) reported its financial results for the third fiscal quarter ending December 31, 2014.
MFS.VN: 0.100 (-0.020)
Leading 100 Medical Devices Companies of USA/Canada 2015
M2 - Mon Mar 23, 10:12AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9k2tjj/usacanada) has announced the addition of the "USA/Canada Medical Devices 100: An Industry Report" report to their offering. The United States is the largest medical device market in the world with a market size of around $110 billion, and it is expected to reach $133 billion by 2016 The U.S. market value represented about 38 percent of the global medical device market in 2012. The U.S. medical device companies are highly regarded globally for their innovations and high technology products. Canada's medical device market ranks as the ninth largest in the world. Canada has an estimated around $7 billion medical device market accounting for about 2 percent of the global market. The market is projected to increase at a CAGR of 4.0% to reach US$8.3bn by 2018. Around 80% of the market is supplied by imports, principally from the USA. With this special industry report, our endeavor is to provide the new investors with a complete resourceful research report for familiarizing with the present investment trends in USA/Canadian medical devices industry, which they would find beneficial to pursue for making business decisions in this sector. Report Highlights: - Leading 100 medical devices companies of USA/Canada - Integration of company news and industry news, as well as rankings and stock market performances - Important M&A and alliances with foreign companies - International presence of USA/Canadian medical devices companies - R&D activities in the industry Report Includes Companies Engaged in: - Manufacturing medical equipments/devices that have life span of more than one year and that can be used repeatedly on multiple patients or multiple medical tests can be done by using them - Manufacturing medical devices providing any medical activity and/or treatment - Manufacturing diagnostic devices - Manufacturing high-tech medical instruments - Manufacturing life-support medical devices Key Features: - Financial information compiled from reliable primary and secondary sources - Business news and transactions compiled from primary news sources, company websites, and press releases - Original news source links provided for each news for further reference - Senior colleagues who analyze news have years of experience Companies Mentioned (Partial List) - Harvard Bioscience, Inc. (United States) - Hasco Medical, Incorporation (United States) - Heartware International Inc (United States) - HEI Inc (United States) - Hill-Rom Holdings, Incorporation (United States) - Hologic, Inc. (United States) - IDEXX Laboratories Inc (United States) - Illumina, Inc. (United States) - Imris Incorporation (Canada) - Inogen Inc (United States) - Insulet Corporation (United States) - Integra LifeSciences Holdings Corporation (United States) - Invacare Corporation (United States) - IRIDEX Corporation (United States) - Lifeline Scientific, Inc (United States) - Lifeloc Technologies Inc (United States) - Medifocus Inc (Canada) For more information visit http://www.researchandmarkets.com/research/9k2tjj/usacanada
IRIX: 8.31 (+0.23), ILMN: 219.45 (+2.28), HBIO: 5.34 (+0.16), PODD: 31.26 (+0.76), IART: 63.06 (+0.98), IVC: 20.62 (+0.25), IMRS: 0.02 (-0.01), INGN: 43.74 (+0.89), IDXX: 64.09 (+1.22), HRC: 54.12 (+0.74), HOLX: 38.71 (+0.75)
Medifocus, Inc. Obtains Two Newly Allowed Canadian Patents on the Prevention and Safety for the Treatment for Breast Cancer
Marketwired - Mon Dec 15, 7:30AM CST
Medifocus Inc. (OTCQX: MDFZF) (TSX VENTURE: MFS) is pleased to announce it has obtained two newly allowed Canadian patents to add to its extensive intellectual properties portfolio of over 100 issued and/or pending USA and Foreign patents covering its two platform technologies for the treatments of Breast Cancer and Prostate Diseases.
MFS.VN: 0.100 (-0.020)
